A5070915452- Neuroscience and Neuropharmacology Research
- Neurological disorders and treatments
- Parkinson's Disease Mechanisms and Treatments
- Neurotransmitter Receptor Influence on Behavior
- Receptor Mechanisms and Signaling
- Neuroscience and Neural Engineering
- Genetic Neurodegenerative Diseases
- Diet and metabolism studies
- Neurogenesis and neuroplasticity mechanisms
- Treatment of Major Depression
- Transcranial Magnetic Stimulation Studies
- Neuroinflammation and Neurodegeneration Mechanisms
- Photoreceptor and optogenetics research
- Advanced MRI Techniques and Applications
- Nerve injury and regeneration
- Electromagnetic Fields and Biological Effects
- Mitochondrial Function and Pathology
- Schizophrenia research and treatment
- Pluripotent Stem Cells Research
- Medicinal Plants and Neuroprotection
- Alzheimer's disease research and treatments
- Cholinesterase and Neurodegenerative Diseases
- Olfactory and Sensory Function Studies
- Nicotinic Acetylcholine Receptors Study
- Vitamin C and Antioxidants Research
Institut de Biologie du Développement Marseille
2011-2024
Centre National de la Recherche Scientifique
2008-2022
Aix-Marseille Université
2009-2021
Institut de Microbiologie de la Méditerranée
2011
Infection et inflammation
2005
Mécanismes Centraux et Périphériques de la Neurodégénérescence
2004
Bayer (Germany)
1998-2004
AVL (France)
1995-2001
Servier (France)
1999-2000
Centre Hospitalier Universitaire de Saint-Pierre
1978
The present study evaluated, via a combined electrophysiological and dialysis approach, the potential influence of serotonin (5-HT)(2C) as compared to 5-HT(2A) 5-HT(2B) receptors on dopaminergic, adrenergic, serotonergic transmission in frontal cortex (FCX). Whereas selective antagonist MDL100,907 failed modify extracellular levels dopamine (DA), noradrenaline (NA) or 5-HT simultaneously quantified single dialysate samples freely-moving rats, 5-HT(2B)/5-HT(2C) SB206,553 dose-dependently...
Abstract There is growing experimental evidence for the implication of glutamate‐mediated mechanisms both in pathophysiology Parkinson's disease and development dyskinesias with long‐term administration l ‐3,4‐dihydroxyphenylalanine ( ‐DOPA). However, impact this treatment on glutamate transmission basal ganglia has been poorly investigated. In study, we examined effects 6‐hydroxydopamine‐induced lesion nigral dopamine neurons or without subsequent chronic ‐DOPA several parameters system...
Evidence exists that a reinforcement in monoaminergic transmission the frontal cortex (FCX) is associated with antidepressant (AD) properties. Herein, we examined whether blockade of alpha2-adrenergic receptors modified influence monoamine reuptake inhibitors on FCX levels serotonin (5-HT), noradrenaline (NAD), and dopamine (DA). The selective receptor agonist S 18616 (0.16 mg/kg, s.c.) suppressed extracellular NAD, DA, 5-HT (by 100, 51, 63%, respectively) single dialysates freely moving...
Abstract Alterations of striatal synaptic transmission have been associated with several motor disorders involving the basal ganglia, such as Parkinson’s disease. For this reason, we investigated role group‐III metabotropic glutamate (mGlu) receptors in regulating striatum by electrophysiological recordings and using our novel orthosteric agonist (3 S )‐3‐[(3‐amino‐3‐carboxypropyl(hydroxy)phosphinyl)‐hydroxymethyl]‐5‐nitrothiophene (LSP1‐3081) l ‐2‐amino‐4‐phosphonobutanoate (L‐AP4). Here,...
The solute carrier family SLC25 drives the import of a large diversity metabolites into mitochondria, key cellular structure involved in many metabolic functions. Mutations mitochondrial glutamate SLC25A22 (also named GC1) have been identified early epileptic encephalopathy and migrating partial seizures infancy but pathophysiological mechanism GC1 deficiency is still unknown, hampered by absence an vivo model. This mainly expressed astrocytes principal gate for entry mitochondria. A...
Abstract Hyperactivity of striatal glutamatergic synaptic transmission in response to dopamine depletion plays a major role the pathogenesis parkinsonian motor symptoms. In present study we investigated impact, on this hyperactivity, chronic dyskinesiogenic L‐DOPA treatment, combined or not with high‐frequency stimulation (HFS) subthalamic nucleus (STN). vitro patch‐clamp recordings were performed from spiny neurons hemiparkinsonian rats (intranigral 6‐OHDA injection). Here show that...
This study examined the cellular changes produced in striatum by chronic l -DOPA treatment and prolonged subthalamic nucleus high-frequency stimulation (STN–HFS) applied separately, successively, or association, 6-hydroxydopamine-lesioned rat model of Parkinson's disease (PD). Only animals showing severe -DOPA-induced dyskinesias (LIDs) were included, STN–HFS was for 5 d at an intensity efficient alleviating akinesia without inducing dyskinesias. alone induced FosB/ΔFosB immunoreactivity,...
The thalamic centromedian–parafascicular (CM/Pf) complex, mainly represented by Pf in rodents, is proposed as an interesting target for the neurosurgical treatment of movement disorders, including Parkinson9s disease. In this study, we examined functional impact subchronic high-frequency stimulation (HFS) 6-hydroxydopamine-lesioned hemiparkinsonian rat model. Pf-HFS had significant anti-akinetic action, evidenced alleviation limb use asymmetry (cylinder test). Whereas action was moderate,...
Striatal cholinergic interneurons (CINs) respond to salient or reward prediction-related stimuli after conditioning with brief pauses in their activity, implicating them learning and action selection. This pause is lost animal models of Parkinson's disease. How this signal regulates the striatal network remains an open question. Here, we examine impact CIN firing inhibition on glutamatergic transmission between cortex medium spiny neurons expressing dopamine D1 receptor (D1 MSNs). Brief...
Abstract Nigral depletion of the main brain antioxidant GSH is earliest biochemical event involved in Parkinson’s disease pathogenesis. Its causes are completely unknown but increasing number evidence suggests that glutamate transporters [excitatory amino acid (EAATs)] route by which precursors may enter cell. In this study, we report dopamine (DA) neurons, express excitatory carrier 1, preferentially affected EAAT dysfunction when compared with non‐DA neurons. rat embryonic mesencephalic...
Recent evidence points to a neuroprotective action of bee venom on nigral dopamine neurons in animal models Parkinson's disease (PD). Here we examined whether also displays symptomatic by acting the pathological functioning basal ganglia rat PD models. Bee effects were assessed combining motor behavior analyses and vivo electrophysiological recordings substantia nigra pars reticulata (SNr, output structure) pharmacological (neuroleptic treatment) lesional (unilateral intranigral...
The long-term effects and action mechanisms of subthalamic nucleus (STN) high-frequency stimulation (HFS) for Parkinson's disease still remain poorly characterized, mainly due to the lack experimental models relevant clinical application. To address this issue, we performed a multilevel study in freely moving hemiparkinsonian rats undergoing 5-week chronic STN HFS, using portable constant-current microstimulator. In vivo metabolic neuroimaging by (1) H-magnetic resonance spectroscopy (11.7...
Abstract TP53INP1 is a stress-induced protein, which acts as dual positive regulator of transcription and autophagy whose deficiency has been linked with cancer metabolic syndrome. Here, we addressed the unexplored role its Drosophila homolog dDOR in maintenance neuronal homeostasis under chronic stress, focusing on dopamine (DA) neurons normal ageing- Parkinson’s disease (PD)-related context. Trp53inp1 − / mice displayed additional loss DA substantia nigra compared to wild-type (WT) mice,...